|

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

RECRUITINGPhase 2/3Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
PhasePhase 2/3
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2022-12-20
Est. completion2024-12-20
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05749289

Summary

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with Neuroendocrine Tumor

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with suspected or clearly diagnosed Neuroendocrine Tumor
* signed written consent.
* Willing and able to cooperate with all projects in this study.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions2

CancerNeuroendocrine Tumor

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.